- Home
- INSP vs TGTX Comparison
INSP vs TGTX Comparison
Compare INSP & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSP
- TGTX
- Stock Information
- Founded
- INSP 2007
- TGTX 1993
- Country
- INSP United States
- TGTX United States
- Employees
- INSP N/A
- TGTX N/A
- Industry
- INSP Medical/Dental Instruments
- TGTX Biotechnology: Pharmaceutical Preparations
- Sector
- INSP Health Care
- TGTX Health Care
- Exchange
- INSP Nasdaq
- TGTX Nasdaq
- Market Cap
- INSP 3.8B
- TGTX 4.2B
- IPO Year
- INSP 2018
- TGTX 1995
- Fundamental
- Price
- INSP $80.16
- TGTX $32.16
- Analyst Decision
- INSP Buy
- TGTX Strong Buy
- Analyst Count
- INSP 15
- TGTX 4
- Target Price
- INSP $165.86
- TGTX $42.50
- AVG Volume (30 Days)
- INSP 1.0M
- TGTX 2.1M
- Earning Date
- INSP 11-03-2025
- TGTX 11-03-2025
- Dividend Yield
- INSP N/A
- TGTX N/A
- EPS Growth
- INSP 756.73
- TGTX N/A
- EPS
- INSP 1.74
- TGTX 0.36
- Revenue
- INSP $861,312,000.00
- TGTX $454,069,000.00
- Revenue This Year
- INSP $14.93
- TGTX $82.58
- Revenue Next Year
- INSP $14.34
- TGTX $44.99
- P/E Ratio
- INSP $45.95
- TGTX $89.15
- Revenue Growth
- INSP 22.05
- TGTX 30.96
- 52 Week Low
- INSP $73.92
- TGTX $21.16
- 52 Week High
- INSP $218.52
- TGTX $46.48
- Technical
- Relative Strength Index (RSI)
- INSP 34.66
- TGTX 57.84
- Support Level
- INSP $77.41
- TGTX $31.34
- Resistance Level
- INSP $97.25
- TGTX $32.57
- Average True Range (ATR)
- INSP 4.15
- TGTX 1.13
- MACD
- INSP 0.17
- TGTX 0.54
- Stochastic Oscillator
- INSP 13.86
- TGTX 76.20
About INSP Inspire Medical Systems Inc.
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and Europe wherein, it generates a majority of its revenue from the United States.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.